AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker
Abstract To investigate aldo–keto reductase 1C3 (AKR1C3) expression in T and B acute lymphoblastic leukemia/lymphoma (ALL) patients. Three commercial antibodies were evaluated for AKR1C3 immunohistochemistry (IHC) staining performance: Polyclonal Thermofisher scientific (Clone#PA523667), rabbit mono...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-09697-6 |
| _version_ | 1819210013945626624 |
|---|---|
| author | Deepti Reddi Brandon W. Seaton David Woolston Lauri Aicher Luke D. Monroe Zhengwei J. Mao Jill C. Harrell Jerald P. Radich Anjali Advani Nikolaos Papadantonakis Cecilia C. S. Yeung |
| author_facet | Deepti Reddi Brandon W. Seaton David Woolston Lauri Aicher Luke D. Monroe Zhengwei J. Mao Jill C. Harrell Jerald P. Radich Anjali Advani Nikolaos Papadantonakis Cecilia C. S. Yeung |
| author_sort | Deepti Reddi |
| collection | DOAJ |
| description | Abstract To investigate aldo–keto reductase 1C3 (AKR1C3) expression in T and B acute lymphoblastic leukemia/lymphoma (ALL) patients. Three commercial antibodies were evaluated for AKR1C3 immunohistochemistry (IHC) staining performance: Polyclonal Thermofisher scientific (Clone#PA523667), rabbit monoclonal Abcam [EPR16726] (ab209899) and Sigma/Millipore anti-AKR1C3 antibody, mouse monoclonal, clone NP6.G6.A6, purified from hybridoma cell culture. Initial optimization was performed on cell line controls: HCT116 (negative control); genetically modified cell line HCT116 with AKR1C3 overexpression; Nalm and TF1 cell lines. Twenty normal bone marrows from archival B and T-ALL patient samples were subsequently examined. AKR1C3 expression levels in these samples were evaluated by immunohistochemistry, Protein Wes and quantitative RT-PCR. Sigma/Millipore Anti-AKR1C3 antibody (mouse monoclonal, clone NP6.G6.A6) showed higher specificity compared to rabbit polyclonal antibody by immunohistochemistry. H-score was used to quantify percent of nuclear immunoreactivity for AKR1C3 with varying disease involvement. T-ALL samples had a higher H-score (172–190) compared to B-ALL cases (H-score, 30–160). The AKR1C3 expression in peripheral blood by Protein Wes and RT-qPCR showed concordance in relapsed/refractory and/or minimal residual T-ALL cases. Sigma/Millipore Anti-AKR1C3 antibody and mouse monoclonal, clone NP6.G6.A6 can be used to aid in AKR1C expression of T-ALL and in cases of relapsed/refractory and/or minimal residual disease. |
| first_indexed | 2024-12-23T06:04:26Z |
| format | Article |
| id | doaj.art-d9f0d764d2d24b37b37880b7ec019bff |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-23T06:04:26Z |
| publishDate | 2022-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-d9f0d764d2d24b37b37880b7ec019bff2022-12-21T17:57:35ZengNature PortfolioScientific Reports2045-23222022-04-011211810.1038/s41598-022-09697-6AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarkerDeepti Reddi0Brandon W. Seaton1David Woolston2Lauri Aicher3Luke D. Monroe4Zhengwei J. Mao5Jill C. Harrell6Jerald P. Radich7Anjali Advani8Nikolaos Papadantonakis9Cecilia C. S. Yeung10Department of Laboratory Medicine and Pathology, University of WashingtonFred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research CenterHematology and Medical Oncology, Cleveland ClinicWinship Cancer Institute of Emory UniversityDepartment of Laboratory Medicine and Pathology, University of WashingtonAbstract To investigate aldo–keto reductase 1C3 (AKR1C3) expression in T and B acute lymphoblastic leukemia/lymphoma (ALL) patients. Three commercial antibodies were evaluated for AKR1C3 immunohistochemistry (IHC) staining performance: Polyclonal Thermofisher scientific (Clone#PA523667), rabbit monoclonal Abcam [EPR16726] (ab209899) and Sigma/Millipore anti-AKR1C3 antibody, mouse monoclonal, clone NP6.G6.A6, purified from hybridoma cell culture. Initial optimization was performed on cell line controls: HCT116 (negative control); genetically modified cell line HCT116 with AKR1C3 overexpression; Nalm and TF1 cell lines. Twenty normal bone marrows from archival B and T-ALL patient samples were subsequently examined. AKR1C3 expression levels in these samples were evaluated by immunohistochemistry, Protein Wes and quantitative RT-PCR. Sigma/Millipore Anti-AKR1C3 antibody (mouse monoclonal, clone NP6.G6.A6) showed higher specificity compared to rabbit polyclonal antibody by immunohistochemistry. H-score was used to quantify percent of nuclear immunoreactivity for AKR1C3 with varying disease involvement. T-ALL samples had a higher H-score (172–190) compared to B-ALL cases (H-score, 30–160). The AKR1C3 expression in peripheral blood by Protein Wes and RT-qPCR showed concordance in relapsed/refractory and/or minimal residual T-ALL cases. Sigma/Millipore Anti-AKR1C3 antibody and mouse monoclonal, clone NP6.G6.A6 can be used to aid in AKR1C expression of T-ALL and in cases of relapsed/refractory and/or minimal residual disease.https://doi.org/10.1038/s41598-022-09697-6 |
| spellingShingle | Deepti Reddi Brandon W. Seaton David Woolston Lauri Aicher Luke D. Monroe Zhengwei J. Mao Jill C. Harrell Jerald P. Radich Anjali Advani Nikolaos Papadantonakis Cecilia C. S. Yeung AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker Scientific Reports |
| title | AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker |
| title_full | AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker |
| title_fullStr | AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker |
| title_full_unstemmed | AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker |
| title_short | AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker |
| title_sort | akr1c3 expression in t acute lymphoblastic leukemia lymphoma for clinical use as a biomarker |
| url | https://doi.org/10.1038/s41598-022-09697-6 |
| work_keys_str_mv | AT deeptireddi akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT brandonwseaton akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT davidwoolston akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT lauriaicher akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT lukedmonroe akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT zhengweijmao akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT jillcharrell akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT jeraldpradich akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT anjaliadvani akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT nikolaospapadantonakis akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker AT ceciliacsyeung akr1c3expressionintacutelymphoblasticleukemialymphomaforclinicaluseasabiomarker |